Business Wire

NY-PHILIP-MORRIS-INTL

Share
Public Wants Greater Focus on Science-Based Decision-Making Says New International Survey from Philip Morris International

Philip Morris International Inc. (PMI) (NYSE: PM) today released “In Support of the Primacy of Science ,” a white paper exploring international attitudes regarding the role of science in society, business, and policymaking. The white paper—presenting findings from an independent survey, conducted by Povaddo for PMI, of over 19,000 adults across 19 countries and territories—indicates that citizens around the world want governments, public authorities, and private businesses to prioritize science and facts when tackling critical issues.

The global insights reveal that faith in science is high, with most people surveyed (77 percent) hopeful that advances in science will solve many of society’s biggest problems. Supporting this view, there is also strong interest in businesses prioritizing science, with 90 percent of respondents saying it is important to them that businesses invest continually in science to improve their products.

Despite these positive attitudes, nearly half of respondents (47 percent) believe that society does not place enough importance on science. Given the diverging opinions, the white paper challenges the need for regulators to place greater focus on science to inform policy decisions, with half (51 percent) of respondents believing that their “government does a good job ensuring science and evidence are included in the decision-making process.”

“Science can help make significant strides in our collective efforts to address the world’s most pressing problems” said Dr. Moira Gilchrist, vice president for Strategic & Scientific Communications at PMI. “Unfortunately, governments and broader society have yet to embrace science at its fullest potential, as this global survey shows. Ensuring facts and evidence are given greater prominence in policymaking—over ideology, politics, and unsubstantiated beliefs—will help match the public’s expectations for science to sit at the heart of decisions impacting them and their future.”

The survey also reveals that people’s access to accurate scientific information is far from assured today, with nearly half of the total sample indicating that they find it difficult to access reliable information about scientific developments and relevant studies.

“This finding is alarming and sends a clear signal across business, media, and government that accurately communicating scientific information should remain an important priority,” added Dr. Gilchrist. “When reliable scientific information is in short supply, misinformation, wild guesses, and hearsay can take more space and significantly hamper people’s ability to make informed decisions.”

PMI is undergoing a fundamental transformation into a science- and technology-led company with the aim of delivering a smoke-free future—a future without cigarettes. With the right regulatory encouragement and support from civil society, we believe this goal can be achieved in many countries in 10 to 15 years. Science is central to delivering on this commitment. Since 2008, PMI has invested billions of dollars in developing, testing, and manufacturing better alternatives to cigarettes for adults who would otherwise continue to smoke. These products are the result of nearly two decades of R&D work, underpinned by a rigorous scientific assessment program and led by a team that today includes more than 430 world-class scientists and other experts. We make our scientific findings and methods available for others to scrutinize, we invite independent research into our products, and we encourage a broad, science-based conversation with regulators, scientists, and the public health community about these better alternatives and the role they can play in tobacco control and harm reduction.

To read the “In Support of the Primacy of Science” paper, visit https://www.pmi.com/primacyofscience .

Survey Methodology

Povaddo conducted this online survey on behalf of PMI between June 25 and July 8, 2020. The survey was fielded among 19,100 general population adults ages 21 and older in 19 countries and territories: Argentina, Australia, Brazil, Germany, Hong Kong, Israel, Italy, Japan, Mexico, the Netherlands, Norway, the Philippines, Russia, South Africa, South Korea, Taiwan, the United Kingdom, the United States, and Vietnam. For the overall sample, there is a margin of error of +/- 0.72% at the 95% confidence interval.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company, and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. PMI ships a version of its smoke-free devices and consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities, and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. For more information, please visit www.pmi.com and www.pmiscience.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press release

SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ

Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press release

Safe Software named for the 6th consecutive time in Gartner® Magic Quadrant™ Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder

GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press release

ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c

BitGo sikrer OCC-godkendelse til konvertering til føderalt chartret National Trust Bank13.12.2025 02:12:00 CET | Pressemeddelelse

Sætter ny standard for institutionel digital aktivinfrastruktur med samlet føderal tilsyn BitGo Holdings, Inc. (“BitGo”), virksomheden inden for digital aktivinfrastruktur, annoncerede i dag, at Office of the Comptroller of the Currency (“OCC”) godkendte virksomhedens ansøgning om at konvertere BitGo Trust Company, Inc., et trustselskab registreret i South Dakota, til en nationalbank ved navn BitGo Bank & Trust, National Association (N.A.). Med dagens OCC-godkendelse af konverteringen fungerer BitGos datterselskab af Trust Company nu som BitGo Bank & Trust, National Association (N.A.). BitGo Bank & Trust, N.A. vil operere under et enkelt, ensartet føderalt tilsynssystem, der gør det muligt at levere den klarhed, styring og reguleringssikkerhed, som institutioner forventer af et føderalt reguleret fiduciært selskab. Denne godkendelse styrker BitGos position som et institutionelt fundament for det moderne finansielle system, der kombinerer tilsyn på bankniveau med den sikkerhed, complian

FIA, Formula 1 Group and All 11 Race Teams Officially Sign the Ninth Concorde Agreement, Securing Strength and Stability for the Sport in Pivotal Five-Year Agreement12.12.2025 17:10:00 CET | Press release

Multi-year Concorde Governance Agreement signed by the FIA, Formula 1 Group and all 11 teams, securing the World Championship through 2030 Paves the way for a more professionalised sport and represents a new era of collaboration between the FIA and Formula 1 Group Long-term commitment enhances sporting reliability, global reach and stability for teams, fans and broadcasters The Fédération Internationale de l'Automobile (FIA), the global governing body for motor sport and the federation for mobility organisations worldwide, and Formula 1 Group, the Commercial Rights Holder, have today announced the signing of the Concorde Governance Agreement, a crucial contract defining the regulatory framework and governance terms of the FIA Formula One World Championship until 2030. This follows the announcement in March that the 2026 Commercial Concorde Agreement had been signed by all the teams and Formula 1 Group. Together, these agreements constitute the ninth Concorde Agreement, representing a m

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye